MeiraGTx Stock Gains 5% Over Narrower Loss In FY25, FDA Breakthrough Designation For AAV2-hAQP1

Shares of MeiraGTx jumped about 5% after the company reported FY2025 results showing a narrower loss and announced the FDA granted Breakthrough Therapy designation for AAV2-hAQP1 for Grade 2 and 3 late xerostomia. The Breakthrough designation materially improves the drug's regulatory pathway and could raise the program's valuation and investor interest, while the narrower FY25 loss eases near-term funding concerns.

Analysis

Shares of MeiraGTx jumped about 5% after the company reported FY2025 results showing a narrower loss and announced the FDA granted Breakthrough Therapy designation for AAV2-hAQP1 for Grade 2 and 3 late xerostomia. The Breakthrough designation materially improves the drug's regulatory pathway and could raise the program's valuation and investor interest, while the narrower FY25 loss eases near-term funding concerns.